Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

As Pfizer and BioNTech’s vaccine delivery runs behind schedule in the EU, Merck KGaA is aiming to boost production by accelerating its supply of custom …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck

Nicole DeFeudis

Editor

Conner Mitchell

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Mer­ck KGaA ex­pands its deal with Pfiz­er/BioN­Tech with an eye on a key vac­cine man­u­fac­tur­ing bot­tle­neck

Editor

Sign up to read this article for free.

more like this

Merck KGaA expands its deal with Pfizer/BioNTech with an eye on a key vaccine manufacturing bottleneck